Enzon Pharmaceuticals, Inc.
PEGINTRON(R) Receives a Recommendation for Approval from FDA Advisory Committee for a New Application in Melanoma
Published in Medical Letter on the CDC and FDA, October 25th, 2009
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced that the FDA Oncologic Drug Advisory Committee voted in favor of recommending approval of PEGINTRON® as a treatment in addition to surgery in patients with metastatic melanoma. The product is currently being marketed, manufactured and developed by Schering-Plough. PEGINTRON (Peginterferon alfa-2b) is currently indicated for treatment of chronic hepatitis C in patients 18 years of age or older with compensated liver disease and previously untreated with interferon alpha. PEGINTRON is also indicated for use in combination with REBETOL® (ribavirin) for the treatment of chronic hepatitis C in patients 3 years of age and older with...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Acne Vulgaris
Research from University of Alabama provide new insights into acne vulgaris - Biopharmaceuticals
Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA - Bristol-Myers Squibb Company and AstraZeneca
Study Finds That ONGLYZA saxagliptin When Added to Metformin was Non-Inferior to JANUVIA sitagliptin When Added to Metformin in Reducing Hemoglobin HbA1c in Adults With Type 2 Diabetes Mellitus - Chagas Disease
Studies from University of California reveal new findings on Chagas disease - Clinical Trial Research
ProUroCare Medical Completes Multiple Site Clinical Study for Imaging Prostate Abnormalities - Cystic Fibrosis
Results Published In Journal of Cystic Fibrosis Confirm CREON(R) (pancrelipase) Delayed-Release Capsules Improves Fat Absorption in Patients With Cystic Fibrosis - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
